Medpace (NASDAQ:MEDP) CEO August Troendle Sells 27,174 Shares of Stock

Posted by Stanley Muller on Aug 21st, 2026

Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report) CEO August Troendle sold 27,174 shares of Medpace stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $618.79, for a total value of $16,814,999.46. Following the transaction, the chief executive officer directly owned 561,195 shares of the company’s stock, valued at $347,261,854.05. This trade represents a 4.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Medpace Stock Up 1.3%

Shares of Medpace stock traded up $8.11 on Friday, hitting $620.75. The company’s stock had a trading volume of 225,439 shares, compared to its average volume of 347,887. The company has a market capitalization of $17.33 billion, a P/E ratio of 36.39, a price-to-earnings-growth ratio of 2.71 and a beta of 1.15. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The firm has a fifty day moving average price of $547.09 and a 200-day moving average price of $491.80.

Medpace (NASDAQ:MEDP – Get Free Report) last posted its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same period last year, the firm posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Institutional Trading of Medpace

Several hedge funds and other institutional investors have recently bought and sold shares of MEDP. Johnson Financial Group Inc. purchased a new position in shares of Medpace during the 2nd quarter worth $27,000. Elyxium Wealth LLC acquired a new position in Medpace in the fourth quarter valued at $30,000. Jones Financial Companies Lllp purchased a new position in Medpace during the second quarter worth about $30,000. Allied Private Wealth LLC purchased a new position in Medpace during the second quarter worth about $31,000. Finally, Kilter Group LLC acquired a new stake in Medpace in the 2nd quarter worth about $31,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and lifted their price objective for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. Mizuho raised their price target on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 price target on Medpace in a report on Thursday, July 23rd. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Robert W. Baird boosted their target price on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, Medpace presently has an average rating of “Hold” and an average target price of $584.18.

Read Our Latest Stock Analysis on Medpace

About Medpace

(Get Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.